Based on the research above and our results, we believe that blocking the PD-1 pathway completely may lead to better treatment outcomes in cHL than blocking either the PD-L1 or PD-L2 pathway. This evidence concerns the gene PDCD1LG2 and classic Hodgkin lymphoma.